Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1 IPO registration
- 3.1 EX-3.1
- 3.2 EX-3.2
- 4.3 EX-4.3
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 14.1 EX-14.1
- 21.1 EX-21.1
- 23.1 EX-23.1
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- EX-FILING FEES Ex-filing Fees
Associated filings
- 13 Nov 23 424B3 Prospectus supplement
- 18 Sep 23 424B3 Prospectus supplement
- 4 Aug 23 424B4 Prospectus supplement with pricing info
- 4 Aug 23 424B1 Prospectus with pricing info
- 3 Aug 23 EFFECT Notice of effectiveness
- 28 Jul 23 S-1/A IPO registration (amended)
- 25 Jul 23 S-1/A IPO registration (amended)
- 21 Jul 23 S-1/A IPO registration (amended)
- 18 Jul 23 S-1/A IPO registration (amended)
- 14 Jul 23 S-1/A IPO registration (amended)
-
29 Jun 23 S-1 IPO registration
MIRA similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Accountants
We hereby consent to the incorporation by reference in this Registration Statement and Prospectus of MIRA Pharmaceuticals, Inc., of our report dated April 4, 2023, with respect to our audits of the financial statements of MIRA Pharmaceuticals, Inc. as of December 31, 2022 and 2021 and for each of the years in the two-year period ended December 31, 2022. We also consent to the reference to us under the heading “Experts” in such Registration Statement and Prospectus.
/s/ Cherry Bekaert LLP
Tampa, Florida
June 29, 2023